LAS VEGAS, Dec. 10, 2014 /PRNewswire/ -- EnzymeBioSystems (OTCBB: ENZB) announces that preclinical xenograft studies with methyl amooranin, its lead pharmaceutical product, show positive results in inhibiting human colon carcinoma.
Xenografting is an established and reliable preclinical method for testing anti-tumor therapies. Xenografting is a scientific technique involving transplantation of tissue from one species to a different species. In particular, xenografting of human tumor tissue into immunocompromised mice provides a better model of tumor cells than in vitro studies.
A study entitled “Anticancer effects of amooranin in human colon carcinoma cell line in vitro and in nude mice xenografts,” appeared in the International Journal of Cancer (2006), concluded methyl amooranin may be advantageous for the inhibition of tumor growth.
Methyl amooranin is a structurally modified version of a plant-based natural product. Management is in the process of preparing the required methyl amooranin studies to apply for an Investigational New Drug Application (“IND”) with the FDA. The Company plans to seek the use of methyl amooranin in the prevention of breast cancer.
“As a precautionary note, there are no assurances that the company will ever obtain an IND for this compound,” stated Gary Rojewski, CEO of EnzymeBioSystems.
About EnzymeBioSystems
EnzymeBioSystems produces specialty enzymes and enzyme related products. The Company plans to use enzyme technologies to develop commercial solutions for a broad range of applications within the pharmaceutical industry.
Included in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The company’s actual results could differ materially from those anticipated in the forward-looking statements.
Contact: Edward Zimmerman III
Phone: (702) 631-4251
ed@tccesq.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/preclinical-xenograft-studies-show-positive-results-for-amooranin-300007923.html
SOURCE EnzymeBioSystems
Help employers find you! Check out all the jobs and post your resume.
